Search

I4MDS consortium: advancing MDS treatment and understanding

The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.

Read more

Reducing bureaucracy in clinical trials: now is the time!

Medical societies and patient advocates across disciplines have joined forces with EHA to call for urgent action to make clinical trials less bureaucratic and more patient-centered, efficient and cheaper.

Read more

Call for urgent action on medicine shortages in Europe

Medicine shortages are an increasing problem across Europe, posing a severe threat to patient outcomes and patient safety. In a new position paper the European Public Health Alliance (EPHA) presents nine recommendations for addressing the shortages crisis.

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more

Highlights of Past EHA (HOPE) Latin America (LA) 2019

Dates: October 4-5, 2019
Location: Mendoza, Argentina
Chairs: 
Prof Dorotea Fantl, President, Sociedad Argentina de Hematología (SAH)
Prof Marivi Mateos, EHA Executive Board Member, European Hematology Association (EHA)

EHA, in partnership with the Sociedad Argentina de Hematología (SAH), is bringing the key messages from the…

Read more